Recursion focuses on diseases where there is a high unmet need – including aggressive cancers and rare diseases. The company is already seeing encouraging data for some of its clinical programs ...

A Solana developer was billed $5,000 for a single query on Google Cloud’s BigQuery, as industry watchers warned of predatory ...

Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 5, Needham reiterated its Buy rating on Recursion Pharmaceuticals, Inc ...

Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (NASDAQ: RXRX) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.

Find annual and quearterly earnings data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) including earnings per share, earnings forecasts at Nasdaq.com.

This article presents analytical, Monte Carlo, and empirical evidence on combining recursive and rolling forecasts when linear predictive models are subject to structural change. Using a ...